- The increasing burden and costs associated with Alzheimer’s disease and other neurodegenerative diseases have made early diagnosis and intervention a national priority. However, conducting clinical trials to develop therapies for diseases like Alzheimer’s is particularly challenging, contributing to higher costs than for many other conditions. Cognitive assessment technology is an important solution to this challenge.
- Applications for cognitive assessment technology extend beyond neurodegenerative diseases. Trial sponsors, regulators and physicians are increasingly interested in measuring and monitoring cognitive function during the drug development process to assess safety and risk for a broad spectrum of drugs. We think digital cognitive assessments, which trial sponsors have recently adopted out of necessity (often due to the pandemic) will continue to grow in popularity.
- We highlight some of the companies providing cognitive assessment technology to trial sponsors for a variety of applications. Their capacity to improve understanding of cognition in healthcare offers enormous promise for technology providers, pharmaceutical companies, and quality of life.
AUTHOR:
Joseph Mundo, First Analysis
LINK TO PUBLICATION:
Mind’s role in therapeutics, wellness means opportunity for cognitive assessment technology